SARS-CoV-2
Conditions
Brief summary
This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants Aged 18 years and over in China
Interventions
BIOLOGICALCOVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose
50μg/dose
BIOLOGICALCOVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose
100μg/dose
DRUGPlacebo
Saline solution
Sponsors
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
The First Affiliated Hospital of Bengbu Medical University
AIM Vaccine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age at the time of first dose of vaccine: adults aged 18-59 years (including boundary values), elderly ≥60 years, both sexes; * Armpit temperature \<37.3℃ on the day of enrollment; * Based on the medical history and relevant physical examination and laboratory examination results, the investigator clinically determined that the patient was in good health; * Subjects have independent judgment ability, can read, understand and complete vaccination diary cards, and they participate voluntarily and sign an informed consent form.
Exclusion criteria
* The subject has a history of SARS-CoV-2 or SARS infection, or has a history of contact with SARS-CoV-2 infected persons (nucleic acid test positive) or suspected infected persons within 30 days before screening, or living abroad within 30 days before screening history, or a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 IgM or IgG test before the first dose of vaccine; * History of allergy to any component of the study vaccine or a history of a severe allergic reaction to the vaccine or drug (including but not limited to anaphylactic shock, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, or local anaphylactic necrosis \[Arthus reaction\]); * Upon questioning, have a history of COVID-19 vaccination, or have received other inactivated vaccines within 14 days before screening, and received live attenuated vaccines within 28 days; * Patients have a medical history or family history of epilepsy, convulsions, neurological diseases and mental diseases; * There are contraindications for intramuscular injection, such as: thrombocytopenia that has been diagnosed, any coagulation disorder or receiving anticoagulant treatment, etc.; * The investigator judges that he is known or suspected of having more serious diseases at the same time, including but not limited to: respiratory diseases (tuberculosis, lung failure, etc.), liver and kidney diseases, cardiovascular diseases (heart failure, severe hypertension, etc.), Malignant tumor, infection or allergic skin disease, HIV infection (test report can be provided), or during the active period of acute infection or chronic disease (within 3 days before vaccination); * Congenital malformations, developmental disorders, or chronic diseases that the investigator judges are not suitable for participating in this study (such as Downs syndrome, sickle cell anemia or neurological disorders, Guillain-Barre syndrome, etc.), excluding stable diabetes/hypertension ); * Patients with known immunological impairment or low immunological function diagnosed by the hospital before enrollment, or functional asplenia or splenectomy caused by any situation; * Smokers (≥20 cigarettes per day on average in the past 30 days), alcoholics (≥61 grams of pure alcohol per day on average for men and ≥41 grams of pure alcohol per day for women in the past 30 days) and drug abuse; * Female: those who have a positive blood pregnancy test, are pregnant, breastfeeding, or have a pregnancy plan within one year; men: whose spouse has a pregnancy plan within one year; * Patients have participated in other clinical trials (drugs, biological products or devices) within 3 months before the first dose of vaccine, or plan to participate in other clinical trials during the research period; * Patients received immune enhancement or immunosuppressive therapy within 6 months before the first dose of vaccine (continuous oral or instillation for more than 14 days); * Patients donated blood ≥400 ml within 28 days before screening, or received whole blood, plasma and immunoglobulin therapy within 6 months before screening; * Currently receiving research drug treatment to prevent COVID-19; * Patients are taking antipyretic, analgesic and anti-allergic drugs within 3 days before enrollment; * The investigator judges that the subjects cannot follow the research procedures, comply with the agreement, or plan to permanently relocate from the area before the end of the research, or plan to leave the local area for a long time during the scheduled visit period; * The relevant staff involved in this study or their immediate family members (such as spouses, parents, siblings or children); * According to the investigator's judgment, there are other situations that are not suitable for participating in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of solicited adverse events | Within 28 days after each dose/full dose |
| Incidence of unsolicited adverse events | Within 28 days after each dose/full dose |
| Incidence of adverse events associated with the study vaccine | Within 28 days after each dose/full dose |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of SAE | Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization |
| Incidence of AESI | Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization |
| Incidence of grade ≥3 adverse events | Within 28 days after each dose/full dose |
| Incidence of AESI associated with the study vaccine | Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization |
| Incidence of clinically significant abnormalities in laboratory measures | After vaccination |
| Incidence of SAE associated with the study vaccine | Within 28 days, 3 months, 6 months, and 12 months after the first dose of immunization to full immunization |
| Incidence of grade ≥3 adverse events associated with the study vaccine | Within 28 days after each dose/full dose |
| Statistics of withdrawal from the study due to adverse events | Within 28 days after each dose/full dose |
Other
| Measure | Time frame |
|---|---|
| Level of cellular immune responses against Novel Coronavirus 2019 (IL-13) | 14 and 28 days after the first dose and 7, 14, 28 days after the full course of vaccination |
| The positive conversion rate of S-protein specific antibody (IgG) against Novel coronavirus 2019 | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| Level of cellular immune responses against Novel Coronavirus 2019 (IFN-γ) | 14 and 28 days after the first dose and 7, 14, 28 days after the full course of vaccination |
| The geometric mean titers (GMT) of S protein-specific antibody (IgG) against Novel coronavirus 2019 | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| The average growth fold compared with the baseline before exemption of S protein-specific antibody (IgG) against Novel coronavirus 2019 | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| Positive conversion rates of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| Positive conversion rates of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| The geometric mean titers (GMT) of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| The average growth fold compared with the baseline before exemption of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) true virus neutralizing antibodies | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| The geometric mean titers (GMT) of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| The average growth fold compared with the baseline before exemption of anti-Novel coronavirus 2019 (Omicron BA.2, BA.4, BA.5 and Delta strains) pseudovirus neutralizing antibodies | 14 and 28 days after the first dose and 7, 14, 28 days, and 3 , 6, and 12 months after the full course of vaccination |
| Level of cellular immune responses against Novel Coronavirus 2019 (IL-2) | 14 and 28 days after the first dose and 7, 14, 28 days after the full course of vaccination |
| Level of cellular immune responses against Novel Coronavirus 2019 (IL-4) | 14 and 28 days after the first dose and 7, 14, 28 days after the full course of vaccination |
Countries
China
Outcome results
None listed